Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 25, 2013

View Archived Issues

Vismodegib + FOLFOX evaluated in gastroesophageal carcinoma

Astex Pharmaceuticals presents phase I results for AT-13387 in GIST

Sorafenib tested in patients with esophageal and gastroesophageal junction cancer

German university presents novel plasmin inhibitors

New acid ceramidase inhibitors patented by CSIC and the Universitat de Barcelona

Merck & Co. synthesizes new DPP-IV inhibitors

New inhibitors of pim-1, pim-2 and/or pim-3 presented by CNIO

Researchers at Tempero Pharmaceuticals design new HDAC9 inhibitors

Rottapharm synthesizes novel EP4 receptor antagonists

Lupin presents new PKM2 activators

Phase III Oral-lyn dossier submitted to Indian government for marketing approval

Gilead initiates phase III program for tenofovir alafenamide in HIV

Novel vitamin E derivative suppresses oxidative stress in animal models of traumatic injury

Amarin launches Vascepa in the U.S.

Vanda Pharmaceuticals reports results from second phase III RESET study

Biogen Idec reports topline results from phase III peginterferon beta-1a trial

Dymista obtains approval in Europe

Curis doses first patient in phase I trial of CUDC-907

Selepressin is beneficial in patients with septic shock

Preclinical studies suggest broad potential for GFT-505 in cirrhosis

Results reported from phase III Japanese studies of KRN-125

Biodel reports topline results from study of ultra-rapid-acting insulin analogue candidates

Orexo and AstraZeneca sign research agreement

Exelixis launches Cometriq in the U.S.

Eurocine Vaccines developing Immunose FLU for pediatric market

Development discontinued of limaprost alfadex for carpal tunnel syndrome

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...